InVivo Therapeutics Holdings Corp. Company Profile
Background
InVivo Therapeutics Holdings Corp., founded in 2005 and headquartered in Cambridge, Massachusetts, is a research and clinical-stage biomaterials and biotechnology company. The company is dedicated to developing innovative therapies for spinal cord injuries (SCI) and other central nervous system disorders. Its mission is to improve the lives of patients suffering from debilitating conditions through groundbreaking research and development.
Key Strategic Focus
InVivo's strategic objectives include:
- Development of Novel Therapies: Creating biopolymer scaffolding devices aimed at promoting neural regeneration and functional recovery in SCI patients.
- Clinical Validation: Conducting rigorous clinical trials to assess the safety and efficacy of its therapeutic products.
- Collaborative Efforts: Partnering with leading scientific and medical experts to enhance research outcomes.
- Regulatory Engagement: Working closely with regulatory bodies to facilitate product development and approvals.
Financials and Funding
As of September 30, 2023, InVivo reported:
- Total Revenue: $0
- Research and Development Expenses: $2.3 million
- General and Administrative Expenses: $1.5 million
- Net Loss: $3.8 million
- Cash and Cash Equivalents: $4.5 million
- Total Assets: $10.1 million
The company has raised approximately $75.2 million in total funding.
Pipeline Development
InVivo's primary product candidate is the Neuro-Spinal Scaffold, designed to promote regeneration and recovery after spinal cord injury. The company is progressing through multiple clinical trials:
- Phase I: Completed in 2020.
- Phase II: Ongoing, with preliminary data expected in late 2024.
Technological Platform and Innovation
InVivo's technological innovations include:
- Neuro-Spinal Scaffold: A proprietary biopolymer scaffold device designed to provide structural support to the spinal cord and promote neurological recovery.
- Biopolymer-Based Scaffolding: Utilizing biocompatible and bioresorbable polymers, such as Poly lactic-co-glycolic acid and Poly-L-Lysine, to support neural regeneration.
Leadership Team
- Dr. Richard M. Toselli, M.D.: President, CEO, Chief Medical Officer, and Director. Dr. Toselli has extensive experience in the medical field and has been instrumental in guiding InVivo's strategic direction.
- Heather Hamel: Chief Legal Officer and General Counsel. Ms. Hamel oversees the company's legal affairs and compliance.
- Pamela Stahl: Chief Commercial Officer. Ms. Stahl leads the company's commercial strategy and operations.
Competitor Profile
Market Insights and Dynamics
The spinal cord injury treatment market is projected to grow significantly, with an estimated market size valued at approximately $2 billion in 2023 and expected to reach around $3.6 billion by 2030, growing at a CAGR of approximately 8.5%.
Competitor Analysis
Key competitors include:
- Medtronic plc: A global leader in medical technology, offering a range of neurotechnology products.
- Boston Scientific Corporation: Provides innovative medical solutions, including neurostimulation devices.
- NeuroPace, Inc.: Specializes in responsive neurostimulation systems for neurological disorders.
- Neurostar, Inc.: Focuses on non-invasive neurostimulation therapies.
- Abbott Laboratories: Offers a diverse portfolio of medical devices, including those for neurological conditions.
Strategic Collaborations and Partnerships
InVivo has established partnerships with various academic and research institutions to facilitate trials and product development, including:
- Massachusetts General Hospital
- Harvard Medical School
- University of California, San Diego
Operational Insights
InVivo operates in a highly competitive environment characterized by rapid innovation and strict regulatory requirements. The company focuses on:
- Research and Development: Investing heavily in R&D to maintain a competitive edge.
- Clinical Trials: Conducting rigorous clinical trials to validate the efficacy and safety of its treatments.
- Regulatory Compliance: Engaging with regulatory bodies to facilitate product development and approvals.
Strategic Opportunities and Future Directions
InVivo's future plans include:
- Achieving FDA Approval: Aiming for FDA approval of its investigational products within the next 2-3 years.
- Expanding Partnerships: Seeking additional collaborations with biotech and pharmaceutical companies.
- Increasing Funding: Exploring equity offerings or grants to support ongoing research efforts.
- Enhancing Educational Outreach: Informing and engaging stakeholders in spinal cord injury research.
Contact Information
- Website: www.invivotherapeutics.com
- Headquarters: Cambridge, Massachusetts
